top of page
This site was designed with the
.com
website builder. Create your website today.Start Now

PUBLICATIONS

For our latest publications, click for Pubmed
2022
Article papers

  1. Hanada, K., Fukasawa, K., Hinata, H., Imai, S., Takayama, K., Hirai, H., Ohfusa, R., Hayashi, Y., Itoh, F. Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model. Cancer Sci. 2022, in press.

  2. Cui, Y.; Taguchi, A.; Shida, H.; Konno, S.; Takayama, K.; Taniguchi, A.; Hayashi, Y. Chemical synthesis of an HIV-1 protease analog with some amides in a polypeptide main chain replaced by disulfide bonds. Bull. Chem. Soc. Jpn. 2022, 95, 1156-1162.

  3. Otani, Y.; Taguchi, A.; Hamada, K.; Hayashi, Y.; Yamaguchi, Y.; Baba, H. Influence of novel readthrough agents on myelin protein zero translation in the peripheral nervous system. Neuropharmacology 2022, 211, 109059.

  4. Takayama, K.; Hitachi, K.; Okamoto, H.; Saitoh, M.; Odagiri, M.; Ohfusa, R.; Shimada, T.; Taguchi, A.; Taniguchi, A.; Tsuchida, K.; Hayashi, Y. Development of Myostatin Inhibitory d-Peptides to Enhance the Potency, Increasing Skeletal Muscle Mass in Mice. ACS Med. Chem. Lett. 2022, 13, 492–498.

Review papers
2021
Article papers

  1. Asari, T.; Ikeyama, H.; Taguchi, A.; Taniguchi, A.; Hayashi, Y.; Takayama, K. Proposal for the binding mode of the 23-mer inhibitory peptide to myostatin. Bioorg. Med. Chem. 2021, 40, 116181.

  2. Hoshi, M.; Shiino, S.; Gomi, A.; Sakata, K.; Konno, S.; Hayashi, Y.; Kojima, M. In silico Design of Inhibitor Against SARS-CoV-2 Protease by Docking Simulation and ADMET Prediction. Bioimages in press.

  3. Konno, S.; Kobayashi, K.; Senda, M.; Funai, Y.; Seki, Y.; Tamai, T.; Schäkel, L.; Sakata, K.; Pillaiyar, T.; Taguchi, A.; Taniguchi, A.; Gütschow, M.; Müller, C. E.; Takeuchi, K.; Hirohama, M.; Kawaguchi, A.; Kojima, M.; Senda, T.; Shirasaka, Y.; Kamitani, W.; Hayashi, Y. 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV‐2 Agents. J. Med. Chem. 2021, 65, 2926-2939.

  4. Kobayakawa, T.; Azuma, C.; Watanabe, Y.; Sawamura, S.; Taniguchi, A.; Hayashi, Y.; Tsuji, K.; Tamamura, H. Development of Methods for Convergent Synthesis of Chloroalkene Dipeptide Isosteres and Its Application. J. Org. Chem. 2021, 86, 5091-5101. 

  5. Sasaki, K.; Muguruma, K,; Osawa, R.; Fukuda, A.; Taniguchi, A.; Hayashi, Y.; Kishimura, A.; Mori, T.; Katayama, Y. Synthesis and biological evaluation of a novel, monocyclic Fc-binding antibody-recruiting molecule for cancer immunotherapy. RSC Med. Chem. 2021, 12, 406-409.

  6. Kobayashi, K.; Taguchi, A.; Cui, Y.; Shida, H.; Muguruma, K.; Takayama, K.; Taniguchi, A.; Hayashi, Y. “On-resin” disulfide peptide synthesis with methyl 3-nitro-2-pyridinesulfenate. Eur. J. Org. Chem. 2021, 956-963.

  7. Muguruma, K.; Osawa, R.; Fukuda, A.; Ishikawa, N.; Fujita, K.; Taguchi, A.; Takayama, K.; Taniguchi, A.; Ito, Y.; Hayashi, Y. Development of a high‐affinity antibody‐binding peptide for site‐specific modification. ChemMedChem 2021, 16, 1814-1821.

  8. Uchiyama, C.; Fukuda, A.; Mukaiyama, M.; Nakazawa, Y.; Kuramochi, Y.; Muguruma, K.; Arimoto, M.; Ninomiya, A.; Kako, K.; Katsuyama, Y.; Konno, S.; Taguchi, A.; Takayama, K.; Taniguchi, A.; Nagumo, Y.; Usui, T.; Hayashi, Y. Structural revision of natural cyclic depsipeptide MA026 established by total synthesis and biosynthetic gene cluster analysis. Angew. Chem. Int. Ed. 2021, 60, 8792-8797.

  9. Okamoto, H.; Taniguchi, A.; Usami, S.; Katsuyama, M.; Konno, S.; Taguchi, A.; Takayama, K.; Hayashi, Y. Development of functionalized peptides for efficient inhibition of myostatin by selective photooxygenation. Org. Biomol. Chem. 2021, 19, 199-207.

Review papers
2020
Article papers

  1. Ojima, C.; Noguchi, Y.; Miyamoto, T.; Saito, Y.; Orihashi, H.; Yoshimatsu, Y.; Watabe, T.; Takayama, K.; Hayashi, Y.; Itoh, F. Peptide‐2 from mouse myostatin precursor protein alleviates muscle wasting in cancer‐associated cachexia, Cancer Sci. 2020, 111, 2954-2964.

  2. Cui, Y.; Taguchi, A.; Kobayashi, K.; Shida, H.; Takayama, K.; Taniguchi, A.; Hayashi, Y. Use of solid-supported 4-fluorophenyl 3-nitro-2-pyridinesulfenate in the construction of disulfide- linked hybrid molecules. Org. Biomol. Chem. 2020, 18, 7094-7097.

  3. Takayama, K.; Mori, K.; Asari, T.; Sohma, Y.; Nomura, E.; Sasaki, Y.; Taguchi, A.; Taniguchi, A.; Miyazato, M.; Minamino, N.; Kangawa, K.; Hayashi, Y. Design and synthesis of peptidic partial agonists of human neuromedin U receptor 1 with enhanced serum stability. Bioorg. Med. Chem. Lett. 2020, 30, 127436.

  4. Takayama, K.; Odagiri, M.; Taguchi, A.; Taniguchi, A.; Hayashi, Y. Enzymatic Stability of Myostatin Inhibitory 16-mer Peptides. Chem. Pharm. Bull. 2020, 68, 512-515.

  5. Vares, G.; Jallet, V.; Matsumoto, Y.; Rentier, C.; Takayama, K.; Sasaki, T.; Hayashi, Y.; Kumada, H.; Sugawara, H. Functionalized mesoporous silica nanoparticles for innovative boron-neutron capture therapy of resistant cancers. Nanomedicine 2020, 27, 102195.

  6. Takayama, K.; Mori, K.; Tanaka, A.; Sasaki, Y.; Sohma, Y.; Taguchi, A.; Taniguchi, A.; Sakane, T.; Yamamoto, A.; Miyazato, M.; Minamino, N.; Kangawa, K.; Hayashi, Y. A chemically stable peptide agonist to neuromedin U receptor type 2.  Bioorg. Med. Chem. 2020, 28, 115454.

  7. Taguchi, A.; Kobayashi, K.; Cui, Y.; Takayama, K.; Taniguchi, A.; Hayashi, Y. Disulfide-driven cyclic peptide synthesis of human endothelin-2 with a solid-supported Npys-Cl. J. Org. Chem. 2020, 85, 1495-1503.

  8. Saitoh, M.; Takayama, K.; Hitachi, K.; Taguchi, A.; Taniguchi, A.; Tsuchida, K.; Hayashi, Y. Discovery of a follistatin-derived myostatin inhibitory peptide. Bioorg. Med. Chem. Lett. 2020, 30, 126892. 

  9. Tanaka, A.; Takayama, K.; Furubayashi, T.; Mori, K.; Takemura, Y.; Amano, M.; Maeda, C.; Inoue, D.; Kimura, S.; Kiriyama, A.; Katsumi, H.; Miyazato, M.; Kangawa, K.; Sakane, T.; Hayashi, Y.; Yamamoto, A.; Transnasal delivery of the peptide agonist specific to neuromedin-U receptor 2 to the brain for the treatment of obesity. Mol. Pharmaceutics 2020, 17, 32-39. 

Review papers
2019
Article papers

  1. Cédric Rentier, Kentaro Takayama, Mariko Saitoh, Akari Nakamura, Hiroaki Ikeyama, Akihiro Taguchi, Atsuhiko Taniguchi, Yoshio Hayashi, Design and synthesis of potent myostatin inhibitory cyclic peptides, Bioorg. Med. Chem. (2019) 27, 1437-1443.

  2. Kentaro Takayama, Tomo Asari, Mariko Saitoh, Kei Nirasawa, Eri Sasaki, Yoshimi Roppongi, Akari Nakamura, Yusuke Saga, Takahiro Shimada, Hiroaki Ikeyama, Akihiro Taguchi, Atsuhiko Taniguchi, Yoichi Negishi, and Yoshio Hayashi, Chain-shortened myostatin inhibitory peptides improve grip strength in mice, ACS Med. Chem. Lett. (2019) 10, 985-990.

  3. Hideyuki Okamoto, Atsuhiko Taniguchi, Shoya Usami, Akihiro Taguchi, Kentaro Takayama and Yoshio Hayashi, Inactivation of myostatin by photo-oxygenation using catalyst-functionalized peptides, Chem. Commun. (2019) 55, 9108-9111.

  4. Kyohei Muguruma, Konomi Fujita, Akane Fukuda, Satoshi Kishimoto, Soichiro Sakamoto, Risako Arima, Mayu Ito, Mayu Kawasaki, Shogo Nakano, Sohei Ito, Kanade Shimizu, Akihiro Taguchi, Kentaro Takayama, Atsuhiko Taniguchi, Yuji Ito, Yoshio Hayashi, Kinetics-based structural requirements of human immunoglobulin G binding peptides, ACS Omega (2019) 4, 14390-14397.

  5. Kyohei Muguruma, Mayu Ito, Akane Fukuda, Satoshi Kishimoto, Akihiro Taguchi, Kentaro Takayama, Atsuhiko Taniguchi, Yuji Ito and Yoshio Hayashi, Synthesis and structure-activity relationship studies of IgG-binding peptides focused on the C-terminal histidine residue, Med. Chem. Commun. (2019) 10, 1789-1795.

  6. Keisuke Hamada, Noriko Omura, Akihiro Taguchi, Alireza Baradaran-Heravi, Masaya Kotake, Misaki Arai, Kentaro Takayama, Atsuhiko Taniguchi, Michel Roberge, Yoshio Hayashi, New negamycin-based potent readthrough derivative effective against TGA-type nonsense mutations, ACS Med. Chem. Lett. (2019) 10, 1450-1456.

  7. Keisuke Hamada, Akari Naito, Yu Hamaguchi, Yu Kanesaki, Koji Kasahara, Akihiro Taguchi, Noriko Omura, Yoshio Hayashi, Takeo Usui, Ubr1p-cup9p-ptr2p pathway involves in the sensitivity to readthrough compounds negamycin derivatives in budding yeast, Biosci. Biotechnol. Biochem. (2019) 83, 1889-1892.

Review papers
2018
Article papers

  1. Kyohei Muguruma, Takuya Shirasaka, Daichi Akiyama, Kentarou Fukumoto, Akihiro Taguchi, Kentaro Takayama, Atsuhiko Taniguchi, Yoshio Hayashi, An efficient method for the conjugation of hydrophilic and hydrophobic components by solid-phase-assisted disulfide ligation, Angew. Chem. Int. Ed. (2018) 57, 2170-2173.

  2. Takumi Chinen, Keisuke Hamada, Akihiro Taguchi, Yukihiro Asami, Kazuro Shiomi, Yoshio Hayashi and Takeo Usui, Multidrug Sensitive Yeast Strains, Useful Tools for Chemical Genetics, The Yeast Role in Medical Applications, Waleed Mohamed Hussain Abdulkhair, (2018) 29-51.

  3. Yoshinari Wakiyama, Ko Kumura, Eijiro Umemura, Satomi Masaki, Kazutaka Ueda, Yasuo Sato, Yoko Hirai, Yoshio Hayashi, and Keiichi Ajito, Synthesis and SARs of Novel Lincomycin Derivatives Part 5: Optimization of Lincomycin Analogs Exhibiting Potent Antibacterial Activities by Chemical Modification at the 6- and 7-Positions, J. Antibiot. (2018) 71, 298-317.

  4. Ryo Masuda, Risa Hayashi, Hiroshi Nose, Akihiro Taguchi, Yoshio Hayashi, Hiroyuki Yasui, and Takaki Koide, Development of a Carboplatin Derivative Conjugated with a Collagen-like Triple-helical Peptide, Future Med. Chem. (2018) 10, 619-629.

  5. Yan Cui, Cedric Rentier, Akihiro Taguchi, Kentaro Takayama, Atsuhiko Taniguchi, Yoshio Hayashi, 4-Fluorophenyl 3-nitro-2-pyridinesulfenate as a practical protecting agent for amino acids, J. Pept. Sci. (2018) 24, e3070.

  6. Koushi Hidaka, Tooru Kimura, Rajesh Sankaranarayanan, Jun Wang, Keith F. McDaniel, Dale J. Kempf, Masanori Kameoka, Motoyasu Adachi, Ryota Kuroki, Jeffrey-Tri Nguyen, Yoshio Hayashi, and Yoshiaki Kiso, Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine, J. Med. Chem. (2018), 61, 5138-5153.

  7. Yuki Okada, Kaori Okubo, Keisuke Ikeda, Yoshiaki Yano, Masaru Hoshino, Yoshio Hayashi, Yoshiaki Kiso, Hikari Itoh-Watanabe, Akira Naito, and Katsumi Matsuzaki, Toxic Amyloid Tape: A Novel Mixed Antiparallel/Parallel β-Sheet Structure Formed by Amyloid β-Protein on GM1 Clusters, ACS Chem. Neurosci. (2019) 10, 563-572.

Review papers

  1. Akihiro Taguchi, Keisuke Hamada, Yoshio Hayashi, Chemotherapeutics Overcoming Nonsense Mutation-associated Genetic Diseases: Medicinal Chemistry of Negamycin, J. Antibiot. (2018) 71, 205-214.

  2. 田口　晃弘、小谷　明、袴田　秀樹、林　良雄、環状ペプチド合成に有用なジスルフィド形成試薬Npys-OMeの創製、和光純薬時報, Vol. 86, 2-5, 富士フィルム和光純薬株式会社, 2018.

  3. 林　良雄、髙山　健太郎、ペプチドの構造制御による筋肉増強薬をめざしたマイオスタチン阻害ペプチドの創製、生命機能に迫る分子化学、CSJ Curr. Rev. 30（日本化学会編）、化学同人、2018.

  4. 伊東　祐二、金山　洋介、林　良雄、親和性ペプチドを用いた部位特異的修飾法による抗体の高機能化技術、実験医学（津本浩平編）、Vol. 36, No. 11（７月号）、羊土社、2018.

  5. 林　良雄、薬の本質を理解する「臨床医薬品化学」を拓く、ファルマシア（日本薬学会編）、Vol.54, No. 12, 日本薬学会、2018.

​

2017
Article papers

  1. Tomo Asari, Kentaro Takayama, Akari Nakamura, Takahiro Shimada, Akihiro Taguchi and Yoshio Hayashi, Structural basis for the effective myostatin inhibition of the mouse myostatin prodomain–derived minimum peptide, ACS Med. Chem. Lett. 8, 113-117 (2017).

  2. Hisatoshi Shida, Hiroyuki Okada, Hajime Suzuki, Xianfeng Zhang, Jing Chen, Yasuko Tsunetsugu-Yokota, Yuetsu Tanaka, Fumika Yakushiji and Yoshio Hayashi, HIV-1 susceptibility of transgenic rat-derived primary macrophage/T cells and a T cell line that express human receptors, CyclinT1 and CRM1 genes, Genes Cells 22, 424-435 (2017).

  3. Chihiro Uchiyama, Yukari Miyadera, Yoshio Hayashi and Fumika Yakushiji, One-pot selective synthesis of 2,3-dihydro-4H-furo[3,2-c]coumarins by palladium-catalyzed silver-assisted propargylation/intramolecular 5-exo-dig cyclization, ChemistrySelect 2, 3794-3798 (2017).

  4. Akihiro Taguchi, Kiyotaka Kobayashi, Akira Kotani, Kyohei Muguruma, Misaki Kobayashi, Kentarou Fukumoto, Kentaro Takayama, Hideki Hakamata and Yoshio Hayashi, 3-Nitro-2-pyridinesulfenates as efficient solution and solid-phase disulfide bond forming agents, Chem. Eur. J. 23, 8262-8267 (2017).

  5. Cédric Rentier, Kentarou Fukumoto, Akihiro Taguchi and Yoshio Hayashi, The 3-nitro-2-pyridinesulfenyl group: synthesis and applications to peptide chemistry, J. Pept. Sci. 23, 496-504 (2017).

  6. Fumika Yakushiji, Kyohei Muguruma, Yoshiki Hayashi, Takuya Shirasaka, Ryosuke Kawamata, Hironari Tanaka, Yushi Yoshiwaka, Akihiro Taguchi, Kentaro Takayama, and Yoshio Hayashi, Click strategy using disodium salts of amino acids improves the water solubility of plinabulin and KPU-300, Bioorg. Med. Chem. 25, 3623-3630 (2017).

  7. Kentaro Takayama, Kenji Mori, Akiko Tanaka, Erina Nomura, Yuko Sohma, Miwa Mori, Akihiro Taguchi, Atsuhiko Taniguchi, Toshiyasu Sakane, Akira Yamamoto, Naoto Minamino, Mikiya Miyazato, Kenji Kangawa, and Yoshio Hayashi, Discovery of a human neuromedin U receptor 1-selective hex-apeptide agonist with enhanced serum stability, J. Med. Chem. 60, 5228-5234 (2017).

  8. Kentaro Takayama, Cédric Rentier, Tomo Asari, Akari Nakamura, Yusuke Saga, Takahiro Shimada, Kei Nirasawa, Eri Sasaki, Kyohei Muguruma, Akihiro Taguchi, Atsuhiko Taniguchi, Yoichi Negishi, and Yoshio Hayashi, Development of potent myostatin inhibitory peptides through hydrophobic residue-directed structural modification, ACS Med. Chem. Lett. 8, 751-756 (2017).

  9. Weidong Zhang, Hideyuki Sakoda, Ayako Miura, Koichiro Shimizu, Kenji Mori, Mikiya Miyazato, Kentaro Takayama, Yoshio Hayashi, Masamitsu Nakazato, Neuromedin U suppresses glucose-stimulated insulin secretion in pancreatic β cells, Biochem. Biophys. Res. Commun. 493, 677-683 (2017).

  10. Akihiro Taguchi, Keisuke Hamada, Masataka Shiozuka, Misaki Kobayashi, Saori Murakami, Kentaro Takayama, Atsuhiko Taniguchi, Takeo Usui, Ryoichi Matsuda, and Yoshio Hayashi, Structure-activity relationship study of leucyl-3-epi-deoxynegamycin for potent premature termination codon readthrough, ACS Med. Chem. Lett. 8, 1060-1065 (2017).

Review papers

  1. 六車　共平，林　良雄，ペプチド-薬物複合体の効率的な合成法の開発，Biophilia電子版21号, 特集 論理薬科学－創薬の基盤，ビオフィリア編集委員会，6, 62-68 (2017)

  2. 伊東　祐二 ，金山　洋介，林　良雄，六車　共平，抗体部位特異的修飾法を用いた放射性医薬品の開発，Isotope News (Vol. 755) 2018年 2月号, 22-24 (2017).

2016
Article papers

  1. Kentaro Takayama, Akari Nakamura, Cédric Rentier, Yusaku Mino, Tomo Asari, Yusuke Saga, Akihiro Taguchi, Fumika Yakushiji and Yoshio Hayashi, Effect of N-terminal acylation on the activity of myostatin inhibitory peptides, ChemMedChem 11, 845-849 (2016).

  2. Kyohei Muguruma, Fumika Yakushiji, Ryosuke Kawamata, Daichi Akiyama, Risako Arima, Takuya Shirasaka, Yamato Kikkawa, Akihiro Taguchi, Kentaro Takayama, Takeshi Fukuhara, Tetsuro Watabe, Yuji Ito, Yoshio Hayashi, Novel hybrid compound of a plinabulin prodrug with an IgG binding peptide for generating a tumor selective non-covalent-type antibody-drug conjugate, Bioconjugate Chem. 27, 1606-1613 (2016).

  3. Kentaro Takayama, Akihiro Taguchi, Fumika Yakushiji, and Yoshio Hayashi, Identification of a degrading enzyme in human serum that hydrolyzes a C-terminal core sequence of neuromedin U, Biopolymers 106, 440-445 (2016).

Review papers

  1. Thanigaimalai Pillaiyar, Manoj Manickam, Vigneshwaran Namasivayam, Yoshio Hayashi, and Sang-Hun Jung, An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy, J. Med. Chem. 59, 6595-6628 (2016).

  2. 田口　晃弘、福元　謙太郎、林　良雄、固相担持型ジスルフィド形成試薬の創製とその応用、化学工業、化学工業、2016、67、853-860.

  3. 髙山　健太郎、林　良雄、マウスマイオスタチンプロドメイン配列に由来するマイオスタチン阻害ペプチドの発見、Jasco Report、ジャスコレポート社、2016、58、6-11.

2015
Article papers

  1. Kentaro Takayama, Yuri Noguchi, Shin Aoki, Shota Takayama, Momoko Yoshida, Tomo Asari, Fumika Yakushiji, Shin-ichiro Nishimatsu, Yutaka Ohsawa, Fumiko Itoh, Yoichi Negishi, Yoshihide Sunada, and Yoshio Hayashi, Identification of the minimum peptide from mouse myostatin prodomain for human myostatin inhibition, J. Med. Chem. 58, 1544-1549 (2015).

  2. Akihiro Taguchi, Kentarou Fukumoto, Yuya Asahina, Akihiro Kajiyama, Shunsuke Shimura, Keisuke Hamada, Kentaro Takayama, Fumika Yakushiji, Hironobu Hojo and Yoshio Hayashi, 3-Nitro-2-pyridinesulfenyl-mediated solid-phase disulfide ligation in the synthesis of disulfide bond-containing cyclic peptides, Org. Biomol. Chem. 13, 3186-3189 (2015).

  3. Kentaro Takayama, Kenji Mori, Yuko Sohma, Koji Taketa, Akihiro Taguchi, Fumika Yakushiji, Naoto Minamino, Mikiya Miyazato, Kenji Kangawa, and Yoshio Hayashi, Discovery of potent hexapeptide agonists to human neuromedin U receptor 1 and identification of their serum metabolites, ACS Med. Chem. Lett. 6, 302-307(2015).

  4. Keisuke Hamada, Akihiro Taguchi, Masaya Kotake, Suguru Aita, Saori Murakami, Kentaro Takayama, Fumika Yakushiji, and Yoshio Hayashi, Structure-activity relationship studies of 3-epi-deoxynegamycin derivatives as potent readthrough drug candidates, ACS Med. Chem. Lett. 6, 689-694 (2015).

  5. Yutaka Ohsawa, Kentaro Takayama, Shin-ichiro Nishimatsu, Tadashi Okada, Masahiro Fujino, Yuta Fukai, Tatsufumi Murakami, Hiroki Hagiwara, Fumiko Itoh, Kunihiro Tsuchida, Yoshio Hayashi, and Yoshihide Sunada, The inhibitory core of the myostatin prodomain: its interaction with both type I and type II membrane receptors and potential to treat muscle atrophy, PLoS One 10, e0133713 (2015).

  6. Takumi Chinen, Peng Liu, Shuya Shioda, Judith Pagel, Berati Cerikan, Tien-chen Lin, Oliver Gruss, Yoshiki Hayashi, Haruka Takeno, Tomohiro Shima, Yasushi Okada, Ichiro Hayakawa, Yoshio Hayashi, Hideo Kigoshi, Takeo Usui, and Elmar Schiebel, The γ-tubulin-specific inhibitor gatastatin reveals temporal requirements of microtubule nucleation during the cell cycle, Nat. Commun. 6, 8722 (2015); doi: 10.1038/ncomms9722.

  7. Kentarou Fukumoto, Akihiro Kajiyama, Shunsuke Shimura, Koji Taketa, Shinichiro Kimura, Akihiro Taguchi, Kentaro Takayama, Fumika Yakushiji, and Yoshio Hayashi, Development of a thiol selective solid-supported oligoarginine-conjugating reagent KSH-2, Aisan J. Org. Chem. 4, 1030-1033 (2015).

Review papers
2014
Article papers

  1. Kentaro Takayama, Development of an oligoarginine peptide displaying rapid cell penetration for improved intestinal absorption, YAKUGAKU ZASSHI 134, 55-61 (2014).

  2. Fumika Yakushiji, Masako Haramo, Yukari Miyadera, Chihiro Uchiyama, Kentaro Takayama, and Yoshio Hayashi, Palladium Catalyzed C3-Selective mono-Arylation of 4-Hydroxycoumarin, Tetrahedron Lett. 55, 3316-3318 (2014).

  3. Akihiro Taguchi, Keisuke Hamada, Masaya Kotake, Masataka Shiozuka, Hidemasa Nakaminami, Thanigaimalai Pillaiyar, Kentaro Takayama, Fumika Yakushiji, Norihisa Noguchi, Takeo Usui, Ryoichi Matsuda, and Yoshio Hayashi, Discovery of natural products possessing selective eukaryotic readthrough activity: 3-epi-deoxynegamycin and its leucine adduct, ChemMedChem 9, 2233-2237(2014).

  4. Kentaro Takayama, Kenji Mori, Koji Taketa, Akihiro Taguchi, Fumika Yakushiji, Naoto Minamino, Mikiya Miyazato, Kenji Kangawa, and Yoshio Hayashi, Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2, J. Med. Chem. (2014) 57, 6583-6593.

  5. Yoshiki Hayashi, Haruka Takeno, Takumi Chinen, Kyohei Muguruma, Kohei Okuyama, Akihiro Taguchi, Kentaro Takayama, Fumika Yakushiji, Masahiko Miura, Takeo Usui and Yoshio Hayashi, Development of a new benzophenone-diketopiperazine-type potent anti-microtubule agent possessing a 2-pyridine structure, ACS Med. Chem. Lett. 5, 1094-1098 (2014).

Review papers
2013
Article papers

  1. Sho Konno, Kiyohiko Nakada, Pillaiyar Thanigaimalai, Rie Kakiuchi, Takehito Yamamoto, Kentaro Takayama, Yuri Yamazaki, Fumika Yakushiji, Kenichi Akaji, Yoshiaki Kiso, Yuko Kawasaki, Ernesto Freire, and Yoshio Hayashi, Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety, Bioorg. Med. Chem. 21, 412-424 (2013).

  2. Fumika Yakushiji, Yuko Miyamoto, Yuki Kunoh, Reiko Okamoto, Hidemasa Nakaminami, Yuri Yamazaki, Norihisa Noguchi, Yoshio Hayashi, Novel Hybrid-Type Antimicrobial Agents Targeting the Switch Region of Bacterial RNA Polymerase, ACS Med. Chem. Lett. 4, 220-224 (2013).

  3. Pillaiyar Thanigaimalai, Sho Konno, Takehito Yamamoto, Yuji Koiwai, Akihiro Taguchi, Kentaro Takayama, Fumika Yakushiji, Kenichi Akaji, Yoshiaki Kiso, Yuko Kawasaki, Shen-En Chen, Aurash Naser-Tavakolian, Arne Schön, Ernesto Freire, and Yoshio Hayashi, Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: Structure–activity relationship study, Eur. J. Med. Chem. 65, 436-447 (2013).

  4. Yoshio Hayashi, Yuri Yamazaki-Nakamura, and Fumika Yakushiji, Medicinal chemistry and chemical biology of diketopiperazine-type anti-microtubule and vascular disrupting agents, Chem. Pharm. Bull. (Review) 61, 889-901(2013).

  5. Pillaiyar Thanigaimalai, Sho Konno, Takehito Yamamoto, Yuji Koiwai, Akihiro Taguchi, Kentaro Takayama, Fumika Yakushiji, Kenichi Akaji, Shen-En Chen, Aurash Naser-Tavakolian, Arne Schӧn, Ernesto Freire, and Yoshio Hayashi, Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies, Eur. J. Med. Chem. 68, 372-384(2013).

Review papers

  1. 薬師寺文華、バンコマイシンの部位選択的脱酸素化が示す立体配座効果、ファルマシア（トピックス）、2013年１月号.

bottom of page